Cardinal Health — Apr 30, 2026 release

This updated guidance reflects: Improved operating segment performance: • Pharmaceutical and Specialty Solutions segment profit growth of 22% to 23%, from the prior range of 20% to 22% • Other segment profit growth of 36% to 38%, from the prior range of 33% to 35% Net below-the-line improvements: • Non-GAAP effective tax rate decreased to approximately 19%, from the prior range of 21% to 23% • Diluted weighted average shares outstanding decreased to approximately 237 million, from the prior outlook of 237 million to 238 million • Interest and Other expense updated to approximately $340 million, from the prior guidance of approximately $325 million Improved free cash flow: • Adjusted free cash flow raised and narrowed to $3.3 billion to $3.7 billion, from prior guidance of $3.0 billion to $3.5 billion Recent highlights • Cardinal Health announced a significant expansion of its Actinium-225 (Ac-225) production capabilities at its Nuclear and Precision Health Solutions Center for Theranostics Advancement (CTA) in Indianapolis, Indiana, substantially increasing supply for use in investigational therapeutic drug products and future commercial manufacturing novel therapies. • Specialty Networks and The Specialty Alliance entered an arrangement to partner in supporting a pharma company on a multi-year study focused on understanding real world outcomes. Patients will receive care at community gastroenterology clinics across the country with Specialty Networks performing the analysis of the results. • Cardinal Health reduced debt, completing $100M term loan payment ahead of schedule and lowered its leverage ratio 5 to 3.0X, maintaining its targeted range of 2.75 - 3.25X and its investment grade rating. • Cardinal Health recently completed an additional $250 million accelerated share repurchase program, bringing year-to-date share repurchases in fiscal year 2026 to $1.0 billion. Cardinal Health Page 4 Webcast Cardinal Health will host